{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:13:19Z","timestamp":1767705199421},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2018,7,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Cyclodextrins (CDs) are versatile excipients with an essential role in drug delivery, as\nthey can form non-covalently bonded inclusion complexes (host-guest complexes) with several drugs either in\nsolution or in the solid state.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods: <\/jats:title>\n<jats:p>The main purpose of this publication was to carry out a state of the art of CDs as complexing agents in\ndrug carrier systems. In this way, the history, properties and pharmaceutical applications of the CDs were highlighted\nwith typical examples. The methods to enhance the Complexation Efficiency (CE) and the CDs applications\nin solid dosage forms were emphasized in more detail.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> The main advantages of using these cyclic oligosaccharides are as follows: (1) to enhance solubility\/\ndissolution\/ bioavailability of poorly soluble drugs; (2) to enhance drug stability; (3) to modify the drug release\nsite and\/or time profile; and (4) to reduce drug side effects (for example, gastric or ocular irritation). These compounds\npresent favorable toxicological profile for human use and therefore there are various medicines containing\nCDs approved by regulatory authorities worldwide. On the other hand, the major drawback of CDs is the increase\nin formulation bulk, once the CE is, in general, very low. This aspect is particularly relevant in solid dosage forms\nand limits the use of CDs to potent drugs.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> CDs have great potential as drug carriers in Pharmaceutical Technology and can be used by the\nformulator in order to improve the drug properties such as solubility, bioavailability and stability. Additionally,\nrecent studies have shown that these compounds can be applied as active pharmaceutical ingredients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612824666171218125431","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T11:33:54Z","timestamp":1513683234000},"page":"1405-1433","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Cyclodextrins as Drug Carriers in Pharmaceutical Technology: The State of the Art"],"prefix":"10.2174","volume":"24","author":[{"given":"Jaime","family":"Conceicao","sequence":"first","affiliation":[{"name":"UCIBIO-ReQuimTe, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal"}]},{"given":"Oluwatomide","family":"Adeoye","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.ULisboa), Department of Galenic Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Helena Maria","family":"Cabral-Marques","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines and Pharmaceutical Sciences (iMed.ULisboa), Department of Galenic Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Jose Manuel Sousa","family":"Lobo","sequence":"additional","affiliation":[{"name":"UCIBIO-ReQuimTe, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/158395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/158395\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/158395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:49:33Z","timestamp":1608925773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/158395\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":0,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612824666171218125431","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}